beeldscherm schreef op 21 augustus 2018 17:24:
There were no serious or clinically-relevant AEs attributable to any of the prophylactic therapies in the clinical trials.
..
Finally, we will compare results to other cost-effectiveness models of long-term prophylaxis against acute HAE attacks.
het gaat over deze 4 voor diegene die het nog niet wisten,
The interventions assessed in this model are:
?Lanadelumab
?Ruconest(C1 inhibitor,intravenousinjection[recombinant])
?Cinryze (C1 inhibitor,intravenousinjection [human])
?Haegarda (C1 inhibitor,subcutaneous injection [human]